Suppr超能文献

能够有效利用缺乏酪氨酸硫酸化氨基末端的CCR5的1型人类免疫缺陷病毒变体在gp120中存在适应性突变,包括功能性N-聚糖的缺失。

Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.

作者信息

Platt Emily J, Shea Danielle M, Rose Patrick P, Kabat David

机构信息

Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR 97239-3098, USA.

出版信息

J Virol. 2005 Apr;79(7):4357-68. doi: 10.1128/JVI.79.7.4357-4368.2005.

Abstract

By selecting the R5 human immunodeficiency virus type 1 (HIV-1) strain JR-CSF for efficient use of a CCR5 coreceptor with a badly damaged amino terminus [i.e., CCR5(Y14N)], we previously isolated variants that weakly utilize CCR5(Delta18), a low-affinity mutant lacking the normal tyrosine sulfate-containing amino-terminal region of the coreceptor. These previously isolated HIV-1(JR-CSF) variants contained adaptive mutations situated exclusively in the V3 loop of their gp120 envelope glycoproteins. We now have weaned the virus from all dependency on the CCR5 amino terminus by performing additional selections with HeLa-CD4 cells that express only a low concentration of CCR5(Delta18). The adapted variants had additional mutations in their V3 loops, as well as one in the V2 stem (S193N) and four alternative mutations in the V4 loop that eliminated the same N-linked oligosaccharide from position N403. Assays using pseudotyped viruses suggested that these new gp120 mutations all made strong contributions to use of CCR5(Delta18) by accelerating a rate-limiting CCR5-dependent conformational change in gp41 rather than by increasing viral affinity for this damaged coreceptor. Consistent with this interpretation, loss of the V4 N-glycan at position N403 also enhanced HIV-1 use of a different low-affinity CCR5 coreceptor with a mutation in extracellular loop 2 (ECL2) [i.e., CCR5(G163R)], whereas the double mutant CCR5(Delta18,G163R) was inactive. We conclude that loss of the N-glycan at position N403 helps to convert the HIV-1 envelope into a hair-trigger form that no longer requires strong interactions with both the CCR5 amino terminus and ECL2 but efficiently uses either site alone. These results demonstrate a novel functional role for a gp120 N-linked oligosaccharide and a high degree of adaptability in coreceptor usage by HIV-1.

摘要

通过选择R5型人类免疫缺陷病毒1型(HIV-1)毒株JR-CSF,以高效利用氨基末端严重受损的CCR5共受体[即CCR5(Y14N)],我们之前分离出了一些变体,这些变体对CCR5(Delta18)的利用较弱,CCR5(Delta18)是一种低亲和力突变体,缺乏共受体正常的含酪氨酸硫酸酯的氨基末端区域。这些之前分离出的HIV-1(JR-CSF)变体含有仅位于其gp120包膜糖蛋白V3环中的适应性突变。现在,我们通过用仅表达低浓度CCR5(Delta18)的HeLa-CD4细胞进行额外筛选,使病毒不再依赖CCR5氨基末端。适应性变体在其V3环中有额外的突变,以及V2茎中的一个突变(S193N)和V4环中的四个替代突变,这些突变消除了N403位置相同的N-连接寡糖。使用假型病毒的实验表明,这些新的gp120突变都通过加速gp41中依赖CCR5的限速构象变化,而不是通过增加病毒对这种受损共受体的亲和力,对CCR5(Delta18)的利用做出了重要贡献。与这种解释一致,N403位置V4 N-聚糖的缺失也增强了HIV-1对细胞外环2(ECL2)中存在突变的另一种低亲和力CCR5共受体的利用[即CCR5(G163R)],而双突变体CCR5(Delta18,G163R)无活性。我们得出结论,N403位置N-聚糖的缺失有助于将HIV-1包膜转变为一种触发式形式,这种形式不再需要与CCR5氨基末端和ECL2都有强烈相互作用,而是单独使用任何一个位点都能有效利用。这些结果证明了gp120 N-连接寡糖的一种新的功能作用以及HIV-1在共受体使用方面的高度适应性。

相似文献

7
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20.
10
Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
AIDS Res Hum Retroviruses. 1999 May 20;15(8):731-43. doi: 10.1089/088922299310827.

引用本文的文献

2
Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.
J Biol Chem. 2017 Oct 6;292(40):16498-16510. doi: 10.1074/jbc.M117.791731. Epub 2017 Jul 10.
3
Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.
PLoS Pathog. 2016 Dec 19;12(12):e1006098. doi: 10.1371/journal.ppat.1006098. eCollection 2016 Dec.
4
Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1.
AIDS Res Hum Retroviruses. 2015 Oct;31(10):992-8. doi: 10.1089/AID.2015.0131. Epub 2015 Aug 5.
5
Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.
Antiviral Res. 2014 Dec;112:80-90. doi: 10.1016/j.antiviral.2014.10.006. Epub 2014 Oct 24.
9
Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.
Antimicrob Agents Chemother. 2010 Feb;54(2):734-41. doi: 10.1128/AAC.00841-09. Epub 2009 Dec 7.

本文引用的文献

2
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
Science. 2003 Jun 27;300(5628):2065-71. doi: 10.1126/science.1083182.
3
Antibody neutralization and escape by HIV-1.
Nature. 2003 Mar 20;422(6929):307-12. doi: 10.1038/nature01470.
4
T cell dynamics in HIV-1 infection.
Annu Rev Immunol. 2003;21:265-304. doi: 10.1146/annurev.immunol.21.120601.141053. Epub 2001 Dec 19.
8
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20.
10
Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region.
J Biol Chem. 2002 Oct 25;277(43):40397-402. doi: 10.1074/jbc.M206784200. Epub 2002 Aug 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验